The distinct side effect profiles of pan-RAS inhibitors (rash, mucositis) and G12D-specific inhibitors (GI issues) are driving separate clinical strategies. The G12D drugs' better combinability with chemotherapy contrasts with pan-RAS agents, which may be better suited for monotherapy due to toxicity from blocking normal RAS.
The initial success of pan-RAS inhibitors stemmed from a deliberate development strategy. By designing a drug that blocks all RAS variants, not just a specific mutation, developers could efficiently test their compound in the largest possible patient pool, accelerating clinical validation in a disease highly dependent on RAS signaling.
The efficacy of new KRAS inhibitors is set to fundamentally shift pancreatic cancer research. These agents are expected to become the new standard therapeutic backbone, meaning future clinical trials will likely test new drugs in combination with a RAS inhibitor, moving beyond chemotherapy-only combinations.